Annual Conference
Friday 20th June

BSGCT
British Society for Gene and Cell Therapy

08:00 - 09:00	**Registration** (light breakfast) WINDSOR BUILDING FOYER **& Exhibition Hall Opens** WINDSOR ROOMS 002+003, 004 **BSGCT Board Meeting** (08:00-08:45)	
09:00 - 11:05	**SESSION 1 – OPENING PLENARY SESSION** THE WINDSOR AUDITORIUM	Chairs: **Alberto Malerba** and **Professor Rafael J. Yáñez-Muñoz**
09:00 - 09:10	Welcome by Outgoing President **Professor Rafael J. Yáñez-Muñoz**	
09:15 - 09:45	Outstanding Achievement Award Winner Developing gene therapies for rare disease: personal reflections. **Adrian Thrasher, Great Ormond Street Institute of Child Health, University College London**	
09:50 - 10:05	Tumour-selective gene delivery of combinations of immune stimulating agents using the oncolytic, αvβ6 integrin specific virotherapy Ad5NULL-A20 (Fairbairn Award nominee). **Alicia Teijeira Crespo, Cardiff University**	
10:10 - 10:25	Enhanced cell culture medium improves airway epithelial cell transplantation (Fairbairn Award nominee). **Jessica Orr, UCL Great Ormond Street Institute of Child Health, University College London.**	
10:30 - 10:45	Investigating the Mechanisms of Acute Preservation of Cardiac Function Post-Myocardial Infarction Following Angiotensin-(1-9) Gene Therapy (Fairbairn Award nominee). **Iain Black, University of Glasgow**	
10:50 - 11:05	CRISPR activation as therapeutic strategy for Duchenne Muscular Dystrophy (Fairbairn Award nominee). **Rida Javed, Royal Holloway, University of London**	
11:05 -12:00	**Exhibition/ Poster judging** in WINDSOR ROOMS 002+003, 004 & Foyer - with refreshments served	
12:00 - 13:15	**SESSION 2 – PARALLEL SESSIONS**	
	Gene Therapy: Chairs: **Gerry McLachlan & Rida Javed** THE WINDSOR AUDITORIUM	**Cell Therapy:** Chairs**: Ivana Barbaric & Rebeca Gil Garzon** MOORE BUILDING AUDITORIUM
12:00 - 12:20	Translating Genetic Code into Therapeutic Hope - the Application of Antisense Oligonucleotide Therapy for Rare Disease. **Haiyan Zhou, University College London**	The development and manufacture of a Regenerative Macrophage Therapy to treat end-stage liver disease. **Steven Howe, Resolution Therapeutics**
12:25 - 12:45	Bench-to-bedside gene therapy for rare lung diseases. **Uta Griesenbach, Imperial College London**	Cell line identity, safety, and monitoring considerations for cell therapy. **Florian Merkle, University of Cambridge**
12:50 - 13:00	Dual AAV Gene Therapy Strategy for Synaptic Protein Deficiency: Toward a Treatment for Neurodevelopmental Disorders. **Ouidad Khechaoui, University of Sheffield**	Transitioning from Research Innovation to Product Development; Common Challenges and Practical Solutions. **Zoe Hewitt, Regen CTC**
13:05 - 13:15	RNA editing rescues SUDEP and seizure phenotype in a mouse model of Dravet Syndrome. **Ellie Chilcott, EGA Institute for Women's Health, University College London**	Novel Insights into gene editing precision and repair dynamics. **Nathan White, University College London**
13:15 - 14:45	**Exhibition/Poster judging** (until 2pm) in WINDSOR ROOMS 002+003, 004 & Foyer - with lunch served	
14:00 - 14:30	**BSGCT Annual General Meeting (AGM)** – Members Only in the WINDSOR AUDITORIUM	
14:45 - 16:15	**SESSION 3 – JOINT PLENARY -** THE WINDSOR AUDITORIUM. **Chairs: Giulia Massaro & Ellie Chilcott**	
14:45 -15:15	The application of pluripotent stem cells in clinical trials. **Agnete Kirkeby, University of Copenhagen**	
15:20 -15:30	Development of lentiviral gene therapy for progressive familial intrahepatic cholestasis type 3 **Andrei Claudiu Cozmescu, NIHR Great Ormond Street Hospital Biomedical Research Centre, UCL**	
15:35 -15:45	Towards industry 4.0: development of a smart bioprocessing platform integrating real-time monitoring and advanced process control for autologous cell therapy. **Patrick Statham, Cell and Gene Therapy Catapult**	
15:50 -16:00	Preclinical development and in vivo delivery of antisense oligonucleotides for targeted NF1 exon 17 skipping. **Marc Moore, National Horizons Centre, Teesside University**	
16:05-16:15	Systemically delivered mRNA therapy crosses the blood-brain barrier showing neurological benefit in a mouse model of Argininosuccinic Aciduria. **Sonam Gurung, Great Ormond Street Institute of Child Health, University College London**	
16:15 -16:45	**Exhibition Hall Networking** WINDSOR ROOMS 002+003, 004 & Foyer - with refreshments served	
16:45 -17:15	**Closing Session & Awards -** THE WINDSOR AUDITORIUM	
16:45 -16:50	**Closing Remarks from the Incoming President Stuart Nicklin and LOC Co-Chair Zoe Hewitt**	
16:50 -17:15	Awards Presentations	